Prospective Cohort Study on Prognosis of Patients With Hepatitis B/C

Study Overview
=================
Brief Summary
-----------------
Hepatitis B (HBV) and hepatitis C (HCV) are prevalent all over the world, which seriously threatens public health. In 2016, the World Health Organization(WHO) put forward the goal of eliminating the threat of viral hepatitis to public health by 2030. However, at present, the diagnosis rate and treatment rate of chronic HBV and HCV in China are still far from the goal put forward by WHO. Therefore, for China, the elimination of viral hepatitis is still a public health problem that needs a long time to face. This study aims to screen and follow up HBV and HCV patients in Danzhou City, Hainan Province, so as to understand the epidemiological characteristics and long-term prognosis of HBV/HCV patients.

Detailed Description
-----------------
Hepatitis B (HBV) and hepatitis C (HCV) are prevalent all over the world, which seriously threatens public health. According to the survey, there are about 93 million chronic HBV infected people and 10 million chronic HCV infected people in China, accounting for 36.19% and 14.08% of the global HBV and HCV infected people respectively. Chronic HBV and HCV infection is the main cause of liver cirrhosis and liver cancer, which places a great burden on the national economy. In 2016, the World Health Organization(WHO) put forward the goal of eliminating the threat of viral hepatitis to public health by 2030, including 90% diagnosis rate, 80% treatment rate and 90% cure rate of viral hepatitis, in order to reduce 65% of viral hepatitis related deaths and reduce the disease burden. However, at present, the diagnosis rate of chronic HBV in China is 18.7%, the treatment rate is 10.8%, the diagnosis rate of chronic HCV is 30%, and the treatment rate is 9%, which are still far from the goal put forward by WHO. Therefore, for China, the elimination of viral hepatitis is still a public health problem that needs a long time to face. This study aims to screen and follow up HBV and HCV patients in Danzhou City, Hainan Province, so as to understand the epidemiological characteristics and long-term prognosis of HBV/HCV patients.

Official Title
-----------------
Prospective Cohort Study on Prognosis of Patients With Hepatitis B/C in Hainan Province Danzhou City

Conditions
-----------------
Hepatitis B, Hepatitis C

Intervention / Treatment
-----------------
* Other: Anti-virus treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: HBsAg/HBV DNA positive or anti-HCV/HCV RNA positive Exclusion Criteria: patients who refused to participate in the study.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Hepatitis B cohort<br>Patients with HBsAg and/or HBV DNA positive; Patients without cirrhosis. | Other: Anti-virus treatment<br>* Anti-virus treatment<br>|
| Hepatitis C cohort<br>Patients with anti-HCV and/or HCV RNA positive; Patients without cirrhosis. | Other: Anti-virus treatment<br>* Anti-virus treatment<br>|
| Cirrhosis cohort<br>Patients diagnosised with cirrhosis; Patients with HBsAg, and/or HBV DNA, and/or anti-HCV and/or HCV RNA positive. | Other: Anti-virus treatment<br>* Anti-virus treatment<br>|
| Liver cancer cohort<br>Patients diagnosised with liver cancer; Patients with HBsAg, and/or HBV DNA, and/or anti-HCV and/or HCV RNA positive. | Other: Anti-virus treatment<br>* Anti-virus treatment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Epidemiological characteristics of hepatitis B and C | Epidemiological characteristics of hepatitis B and C in Danzhou City, Hainan Province | up to 192 weeks | 
| Long-term outcome | Long-term outcome of HBV/HCV infected patients in Danzhou City, Hainan Province | up to 192 weeks | 
| Risk factors | Risk factors for long-term outcome of HBV/HCV infected patients in Danzhou City, Hainan Province | up to 192 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of cirrhosis | Incidence of cirrhosis for HBV/HCV infected patients in Danzhou City, Hainan Province | up to 192 weeks | 
| Incidence of liver cancer | ncidence of liver cirrhosis for HBV/HCV infected patients in Danzhou City, Hainan Province | up to 192 weeks | 
| Hepatic decompensation | Hepatic decompensation rate for HBV/HCV infected patients in Danzhou City, Hainan Province | up to 192 weeks | 
| Survival rate for liver cancer | Survival rate for liver cancer patients in Danzhou City, Hainan Province | up to 192 weeks | 
| Survival rate for cirrhosis | Survival rate for cirrhosis patients in Danzhou City, Hainan Province | up to 192 weeks | 
| HBV interruption rate of perinatal transmission | HBV interruption rate of perinatal transmission in Danzhou City, Hainan Province | up to 192 weeks | 
| HBsAg loss | The HBsAg loss rate of HBV infected patients in Danzhou City, Hainan Province | up to 192 weeks |